InsidersTradesSigma
Track the Legend Biotech Corp share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €5.3bn. The latest transaction was disclosed on 29 June 2026 (Cession). Among the most active insiders: Huang Ying. Every trade is openly available.
Analysts rate Legend Biotech Corp Buy (bullish), based on 14 analysts. Average price target: US$57.17.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Legend Biotech Corp is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It is listed on NASDAQ under the ticker symbol LEGN.